Week 96 Outcomes in Aflibercept 8 mg- and 2 mg-Treated Participants by Prior DME Treatment Status: a Subgroup Analysis of the Phase 2/3 PHOTON Trial

Basil K Williams Jr MD,[1] on behalf of the PHOTON study investigators

[1]Bascom Palmer Eye Institute, Department of Ophthalmology, Miami, Florida

Presented at the Macula Society Annual Meeting, February 12–15, 2025

Disclosures

- Dr. Williams has worked as a consultant for AbbVie, Alcon, Alimera Sciences, Astellas Pharma, Castle Biosciences, Dorc, EyePoint Pharmaceuticals, Genentech, Immunocore and Regeneron Pharmaceuticals, Inc., and has stock options in Lumata Health
- This study was sponsored by Regeneron Pharmaceuticals, Inc. (Tarrytown, New York) and co-funded by Bayer AG (Leverkusen, Germany). The sponsors participated in the design and conduct of the study, analysis of the data, and preparation of this presentation
- Study disclosures: This study includes research conducted on human patients. Institutional review board approval was obtained prior to study initiation
- Medical writing support was provided by Abbie Rodger, BSc, of Core (a division of Prime, London, UK), funded by Regeneron Pharmaceuticals, Inc. according to Good Publication Practice guidelines

Background

- 44% of participants in PHOTON received prior treatment for DME
- Previous treatments for DME were laser, intravitreal anti-VEGF therapy, and corticosteroids
- We took this opportunity to evaluate visual acuity and anatomic outcomes (CRT and DRSS) in PHOTON participants by prior DME treatment status

CRT, central retinal thickness; DME, diabetic macular edema; DRSS, Diabetic Retinopathy Severity Scale; VEGF, vascular endothelial growth factor.

Baseline Demographics

	With Prior DME Treatment			Without Prior DME Treatment		
	2q8 (n=74)	8q12 (n=146)	8q16 (n=71)	2q8 (n=93)	8q12 (n=182)	8q16 (n=92)
Age, years	64.4 (8.9)	62.7 (10.9)	63.0 (8.4)	62.0 (10.4)	61.6 (11.3)	60.9 (10.3)
Female, %	45.9	39.7	40.8	44.1	33.0	38.0
Race, %						
White	64.9	69.2	77.5	68.8	71.4	79.3
Asian	21.6	19.9	18.3	15.1	10.4	10.9
Black or African American	9.5	7.5	4.2	11.8	13.2	6.5
American Indian or Alaskan Native	0.0	0.7	0.0	0.0	0.5	0.0
Other	2.7	1.4	0.0	2.2	2.2	1.1
Not reported	1.4	1.4	0.0	2.2	1.1	2.2
Hispanic or Latino, %	18.9	17.1	22.5	18.3	15.9	19.6
Duration of diabetes, years	16.7 (10.6)	16.2 (9.4)	16.6 (9.7)	15.5 (9.6)	14.5 (10.3)	15.0 (11.4)

Data are mean (SD) unless otherwise indicated.
SD, standard deviation.

Baseline Ocular Characteristics

	With Prior DME Treatment			Without Prior DME Treatment		
	2q8 (n=74)	8q12 (n=146)	8q16 (n=71)	2q8 (n=93)	8q12 (n=182)	8q16 (n=92)
BCVA, ETDRS letters	62.1 (10.9)	62.2 (10.7)	58.6 (11.9)	61.0 (11.5)	64.8 (9.5)	63.7 (11.2)
Snellen equivalent, %						
20/32 (>73 to 78 letters)	14.9	16.4	5.6	9.7	19.2	20.7
20/40 or worse (≤73 letters)	85.1	83.4	94.4	90.3	80.8	79.3
CRT, µm	472.7 (162.3)	456.9 (123.9)	460.6 (109.3)	444.9 (127.1)	442.9 (130.2)	460.1 (124.7)
DRSS categories, %						
Better or equal to level 43	70.3	66.4	67.6	57.0	54.9	64.1
Level 47 or worse	25.7	28.1	23.9	36.6	39.6	31.5
Missing/ungradable	4.1	5.5	8.5	6.5	5.5	4.3

Data are mean (SD) unless otherwise indicated.
BCVA, best-corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study.

Mean Change in BCVA Through Week 96

With Prior DME Treatment



Without Prior DME Treatment



FAS, observed cases (censoring data post-intercurrent even).
FAS, full analysis set.

Mean Change in CRT Through Week 96

With Prior DME Treatment



Without Prior DME Treatment



FAS, observed cases (censoring data post-intercurrent event).

Proportion of Participants With ≥2-Step DRSS Improvement From Baseline at Week 96

With Prior DME Treatment



Without Prior DME Treatment



FAS, LOCF.
LOCF, last observation carried forward.

Large Proportion of Patients Qualified for Interval Extension in Year 2[a]





[a]Dosing intervals were extended in Year 2 if patients had <5-letter loss in BCVA from Week 12 and CRT <300 µm (or <320 µm on Spectralis). [b]Patients were assigned to 24-week dosing intervals if they continued to meet extension criteria but there was not sufficient time to complete the interval within the 96-week study period. [c]Patients completing Week 96.
Values may not add up to 100% due to rounding.
BL, baseline.

Conclusions

- Proportions of patients with ≥2-step improvement in DRSS score at Week 96 trended numerically higher across all treatment groups in patients without versus with prior DME treatment
- In patients with prior DME treatment, mean BCVA gain from baseline to Week 96 was greater with 2q8 and 8q12 compared with 8q16, suggesting that some patients in this subgroup could have benefited from more frequent treatment
  - This may have been a particularly recalcitrant subgroup as the baseline VA in this group was lower than the other subgroups
- CRT improvements were generally comparable at Week 96 irrespective of prior DME treatment status
- Similar proportions of patients in the 8q12 and 8q16 groups had a last assigned dosing interval of ≥20 weeks at Week 96 irrespective of prior DME treatment status